PATENT CLAIM ANALYSIS

Application Number: 15755958
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "04400R"]

Abstract:
Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.

Claim (Index 7):
The nucleic acid aptamer of  claim 6 , wherein the nucleic acid aptamer consists of the nucleotide acid sequence of SEQ ID NO:2.

Metadata:
- Claim Count in Document: 12.0
- Percentile: 88.0
- Lexical Diversity: 1.13514
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15500345', '15500354', '15239524', '14333375', '15069622']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7959589279641792
- 35 USC 102 Novelty (BERT): 0.5411211225674575
- Combined Prediction Score: 0.7704751474245071
- Mean Citation Score: 336.7336140000001
- Max Citation Score: 393.47345
- Similarity Product: 256.4229496205628

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test